Evidence map›Paper›PMID 34176060›Full record

ArticleAnnals of surgical oncology2021

Surgical Outcomes in Cancer Patients Undergoing Elective Surgery After Recovering from Mild-to-Moderate SARS-CoV-2 Infection.

Anai N Kothari, Sandra R DiBrito, J Jack Lee, Abigail S Caudle, Mark W Clemens, Vijaya N Gottumukkala, Matthew H G Katz, Anaeze C Offodile, Abhineet Uppal, D3CODE Team and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Anai N KothariDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sandra R DiBritoDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abigail S CaudleDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark W ClemensDepartment of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vijaya N GottumukkalaDepartment of Anesthesia and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew H G KatzDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anaeze C OffodileDepartment of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abhineet UppalDepartment of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D3CODE Team
George J ChangDepartment of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. gchang@mdanderson.org.ORCID http://orcid.org/0000-0002-9758-5361
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
National Cancer Institute of the National Institutes of Health CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundAn increasing number of patients with cancer diagnoses and prior SARS-CoV-2 infection will require surgical treatment. The objective of this study was to determine whether a history of SARS-CoV-2 infection increases the risk of adverse postoperative events following surgery in patients with cancer.

methodsThis was a propensity-matched cohort study from April 6, 2020 to October 31, 2020 at the UT MD Anderson Cancer Center. Cancer patients were identified who underwent elective surgery after recovering from SARS-CoV-2 infection and matched to controls based on patient, disease, and surgical factors. Primary study outcome was a composite of the following adverse postoperative events that occurred within 30 days of surgery: death, unplanned readmission, pneumonia, cardiac injury, or thromboembolic event.

resultsA total of 5682 patients were included for study, and 114 (2.0%) had a prior SARS-CoV-2 infection. The average time from infection to surgery was 52 (range 20-202) days. Compared with matched controls, there was no difference in the rate of adverse postoperative outcome (14.3% vs. 13.4%, p = 1.0). Patients with a SARS-CoV-2-related inpatient admission before surgery had increased odds of postoperative complication (adjusted odds ratio [aOR] 7.4 [1.6-34.3], p = 0.01).

conclusionsA minimal wait time of 20 days after recovering from minimally symptomatic SARS-CoV-2 infection appears to be safe for cancer patients undergoing low-risk elective surgery. Patients with SARS-CoV-2 infections requiring inpatient treatment were at increased risk for adverse events after surgery. Additional wait time may be required in those with more severe infections.

Indexed as

COVID-19NeoplasmsCohort StudiesElective Surgical ProceduresHumansSARS-CoV-2Treatment Outcome

Identifiers

PMID34176060
PMCPMC8235912
OpenAlexW3176031771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.